登入/註冊

短合成胜肽及其治療視網膜退化性疾病和/或組織損傷的用途

Taiwan
商機情報
關於
乾式老年性黃斑病變(dry AMD)會造成失明,目前沒有藥物可用於治療。Dry AMD的病理機制是由於視網膜感光細胞外節(POS)代謝的副產物堆積在視網膜色素上皮(RPE)細胞之內,形成猲脂素(lipofuscin),以及堆積在RPE之外,形成隱結(drusen),造成視力減損。因此保護RPE細胞對抗氧化/發炎壓力以及消化感光細胞外節是重要的藥物研發方向。然而目前已知的臨床前藥物開發仍然無法同時解決這些問題。

專利藥6dS製成的眼藥水,可以保護氧化壓力動物的視網膜及RPE細胞,可活化多種細胞保護訊息傳導機制對抗氧化/發炎壓力,避免視網膜和RPE細胞失能及凋亡。此外、6dS分子機制研究證明可以幫助RPE細胞消化感光細胞外節。因此6dS有很大的潛力成為阻止乾式老年性黃斑病變惡化的眼藥水。
特色優勢
1. Fulfill unmet medical need
目前沒有藥物可用於治療 dry AMD。 6dS製成的眼藥水不會引發眼內炎,病人接受度高(由於dry AMD疾病過程緩慢,延續多年,目前開發中的藥物多需重複定期眼內注射,不適合進展緩慢疾病)。

2. First-in-Class drug with clear MOA (6dS是具有明確MOA的創新治療藥劑) -- Our drug provides a novel therapeutic strategy reliance on RPE cell protection and improving POS digestion to alleviate the pathogenesis of dry AMD.

3. Low Toxicity (低毒性) – Our drug is a short peptide derived from a human tissue protein, thus unlikely to have genuine toxicity. The wound healing effect of the 6dS on dry eye syndrome supports its anti-inflammatory and safe topical therapies.

4. Pre-Clinical animal model close to human pathology (臨床前動物模型展現人類dry AMD 病理學的特徵) – The pathological features of our preclinical animal models including NaIO3-induced RPE cell death/dysfunction and I/R-induced retinal degeneration are closely similar to dry AMD. These animal models have been established by inventor’s laboratory for validation of drug bioactivity.

5. Display excellent therapeutic efficacy on dry AMD animals (用dry AMD動物模型驗證,6dS眼藥水可以保護RPE不受氧化壓力傷害,避免視網膜萎縮) -- We have demonstrated that the 6dS eye drop displays excellently effect to suppress NaIO3-induced RPE cell death (TUNEL assay) and cell dysfunction (scotopic electroretinography; ERG). In addition, our eye drop shows significantly effect to suppress ischemia/reperfusion-induced ROS and retinal damage in experimental animals.

6. In vitro model is available to estimate drug activity (體外模型可用於估計藥物活性) – In RPE cell culture, 6dS facilitates POS and lipid droplets digested by lysosomes and protects cell from cell death induced by oxidizing agents, NaIO3 and 4-HNE.

7. No further effort is required to ensure the drug synthesis & quality – 6dS can be synthesized chemically by an automated instrument abiding by GMP standard without any technical issue. The cost of manufacture is acceptable. (6dS是一種短肽衍生物,可以通過符合GMP標準的胜肽合成公司採用自動化儀器進行相關的純肽自動化化學合成,沒有任何技術問題,製造成本是在可接受的範圍)
詳細規格
研發中
尋求技轉授權夥伴

詳細資訊
關於
乾式老年性黃斑病變(dry AMD)會造成失明,目前沒有藥物可用於治療。Dry AMD的病理機制是由於視網膜感光細胞外節(POS)代謝的副產物堆積在視網膜色素上皮(RPE)細胞之內,形成猲脂素(lipofuscin),以及堆積在RPE之外,形成隱結(drusen),造成視力減損。因此保護RPE細胞對抗氧化/發炎壓力以及消化感光細胞外節是重要的藥物研發方向。然而目前已知的臨床前藥物開發仍然無法同時解決這些問題。

專利藥6dS製成的眼藥水,可以保護氧化壓力動物的視網膜及RPE細胞,可活化多種細胞保護訊息傳導機制對抗氧化/發炎壓力,避免視網膜和RPE細胞失能及凋亡。此外、6dS分子機制研究證明可以幫助RPE細胞消化感光細胞外節。因此6dS有很大的潛力成為阻止乾式老年性黃斑病變惡化的眼藥水。
特色優勢
1. Fulfill unmet medical need
目前沒有藥物可用於治療 dry AMD。 6dS製成的眼藥水不會引發眼內炎,病人接受度高(由於dry AMD疾病過程緩慢,延續多年,目前開發中的藥物多需重複定期眼內注射,不適合進展緩慢疾病)。

2. First-in-Class drug with clear MOA (6dS是具有明確MOA的創新治療藥劑) -- Our drug provides a novel therapeutic strategy reliance on RPE cell protection and improving POS digestion to alleviate the pathogenesis of dry AMD.

3. Low Toxicity (低毒性) – Our drug is a short peptide derived from a human tissue protein, thus unlikely to have genuine toxicity. The wound healing effect of the 6dS on dry eye syndrome supports its anti-inflammatory and safe topical therapies.

4. Pre-Clinical animal model close to human pathology (臨床前動物模型展現人類dry AMD 病理學的特徵) – The pathological features of our preclinical animal models including NaIO3-induced RPE cell death/dysfunction and I/R-induced retinal degeneration are closely similar to dry AMD. These animal models have been established by inventor’s laboratory for validation of drug bioactivity.

5. Display excellent therapeutic efficacy on dry AMD animals (用dry AMD動物模型驗證,6dS眼藥水可以保護RPE不受氧化壓力傷害,避免視網膜萎縮) -- We have demonstrated that the 6dS eye drop displays excellently effect to suppress NaIO3-induced RPE cell death (TUNEL assay) and cell dysfunction (scotopic electroretinography; ERG). In addition, our eye drop shows significantly effect to suppress ischemia/reperfusion-induced ROS and retinal damage in experimental animals.

6. In vitro model is available to estimate drug activity (體外模型可用於估計藥物活性) – In RPE cell culture, 6dS facilitates POS and lipid droplets digested by lysosomes and protects cell from cell death induced by oxidizing agents, NaIO3 and 4-HNE.

7. No further effort is required to ensure the drug synthesis & quality – 6dS can be synthesized chemically by an automated instrument abiding by GMP standard without any technical issue. The cost of manufacture is acceptable. (6dS是一種短肽衍生物,可以通過符合GMP標準的胜肽合成公司採用自動化儀器進行相關的純肽自動化化學合成,沒有任何技術問題,製造成本是在可接受的範圍)
詳細規格
研發中
尋求技轉授權夥伴

短合成胜肽及其治療視網膜退化性疾病和/或組織損傷的用途

Taiwan
馬偕紀念醫院 的其他產品
熱門推薦